NIP3-3 Antibody

What is BNIP3 and how does it differ from the parasitic NIP3?

BNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3) is a mammalian protein involved in apoptosis that can overcome BCL2 suppression. It plays crucial roles in mitochondrial quality control and calcium repartitioning between intracellular stores. BNIP3 contains a BH3 domain and participates in the degradation of damaged proteins inside mitochondria through interaction with SPATA18/MIEAP .

In contrast, parasitic NIP3 (such as BmNIP3 from Brugia malayi) represents a novel immunogenic protein with significant homology to Onchocerca volvulus NIP3 and C. elegans NIP3-like protein. BmNIP3 differs structurally, containing three potential mucin-type O-glycosylation sites and several serine/threonine phosphorylation sites. It is predominantly expressed in larval stages (L3 and L4) of the parasite and appears to be highly immunogenic in both humans and mice .

What experimental applications are appropriate for BNIP3 antibodies?

BNIP3 antibodies have been validated for multiple research applications including:

• Western Blotting: Typically using 1:1,000 dilution for cell lysates and 1:10,000 for recombinant proteins

• Immunohistochemistry (Paraffin): Effective at 1:50-1:100 dilution

• Immunocytochemistry: Recommended at 1:100 dilution

• Enzyme Immunoassay (ELISA): Various dilutions for detecting recombinant BNIP3

• Affinity Binding Assays: Capable of binding BNIP3 with high affinity (KD of 7.9 x 10-8)

For parasitic NIP3 research, antibodies have been primarily used in immunoprecipitation and ELISA techniques to analyze immune responses in different clinical groups .

How should researchers select between monoclonal and polyclonal antibodies for BNIP3 detection?

The selection depends on research objectives:

Monoclonal Antibodies (e.g., Anti-BNIP3 clone 1G21 ZooMAb):

• Advantages: Higher specificity targeting defined epitopes, excellent for detecting specific domains/conformations, reduced batch-to-batch variability

• Recommended for: Quantitative analyses, experiments requiring consistent results across multiple studies

• Application notes: A 1:1,000 dilution typically detects BNIP3 in Jurkat cell lysate in Western blotting

Polyclonal Antibodies (e.g., BNIP3 BH3 Domain Specific):

• Advantages: Recognize multiple epitopes, potentially higher sensitivity for low abundance proteins, better for denatured proteins

• Recommended for: Initial studies, proteins with post-translational modifications, detection of low expression targets

• Application notes: Typically used at 1:50-1:100 dilution for IHC-P and IF

Researchers should validate antibody performance in their specific experimental systems regardless of type selected.

What validation steps should be performed before using a new BNIP3 antibody in critical experiments?

A systematic validation approach should include:

• Literature Verification: Review citations for the specific antibody to confirm successful applications in similar experimental conditions

• Positive Control Selection: Use cells/tissues known to express BNIP3 (e.g., Jurkat cells)

• Negative Controls: Include samples with:

  • Primary antibody omission

  • Non-specific IgG substitution

  • BNIP3 knockdown/knockout if available

• Multiple Detection Methods: Cross-validate findings with at least two techniques (e.g., Western blot and IHC)

• Titration Experiments: Test multiple dilutions to determine optimal signal-to-noise ratio

• Specificity Confirmation: For Western blots, verify the band appears at the expected molecular weight (~21 kDa for native BNIP3)

• Peptide Competition: When available, pre-incubate antibody with immunizing peptide to confirm specificity

How can researchers simultaneously assess BNIP3 expression and phosphorylation status?

To simultaneously assess BNIP3 expression and its phosphorylation status, researchers can implement this protocol:

• Immunoprecipitation Preparation:

  • Immobilize anti-BNIP3 antibodies to protein A columns (100 μg antibody, 15 min binding)

  • Wash with binding/wash buffer (5 times)

  • Cross-link antibodies to protein A using DSS cross-linker

  • Remove unbound antibodies with appropriate elution buffer

• Antigen Capture:

  • Incubate 100 μg of soluble antigen with cross-linked antibodies (1 hour, room temperature)

  • Wash thoroughly to remove unbound antigens (5 washes)

  • Elute bound antigens with 200 μl elution buffer

• Detection of Phosphorylation:

  • Resolve immunoprecipitated protein on 12% SDS-PAGE

  • Transfer to nitrocellulose membranes

  • Block with 3% skimmed milk (1 hour, room temperature)

  • Probe with mouse monoclonal phosphoserine/threonine antibody (1:1,000)

  • Develop using appropriate secondary antibody and detection system

• Sequential or Parallel Blotting:

  • Strip and reprobe membrane for total BNIP3, or

  • Run parallel gels for total and phosphorylated protein detection

This approach allows for correlation between total protein expression and post-translational modification status.

What are the optimized protocols for detecting BNIP3 in paraffin-embedded tissue sections?

For optimal detection of BNIP3 in FFPE tissue samples:

• Sample Preparation:

  • Cut sections to 4-6 μm thickness

  • Mount on positively charged slides

  • Deparaffinize with xylene (3×5 min)

  • Rehydrate through graded ethanol series to water

• Antigen Retrieval (critical step):

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Pressure cooker method: 125°C for 3 minutes or 95-100°C for 20 minutes in appropriate buffer

  • Cool slides gradually to room temperature (20 minutes)

• Staining Protocol:

  • Block endogenous peroxidase (3% H₂O₂, 10 minutes)

  • Protein block (5% normal serum, 1 hour)

  • Primary antibody incubation:

    • For rabbit polyclonal: 1:50-1:100 dilution overnight at 4°C

    • For rabbit monoclonal: Follow manufacturer's optimized dilution (typically 1:100)

  • Secondary antibody application (30-60 minutes, room temperature)

  • DAB visualization (3-5 minutes, monitor for signal development)

  • Counterstain with hematoxylin

  • Dehydrate, clear, and mount

• Controls and Validation:

  • Include known positive tissue (human kidney shows reliable BNIP3 expression)

  • Run negative controls (primary antibody omission)

  • Consider multiplex staining with mitochondrial markers for co-localization studies

How should researchers interpret differences in BNIP3 antibody reactivity between human and mouse samples?

When analyzing BNIP3 expression across species, researchers should consider:

• Sequence Homology Assessment:

  • Human and mouse BNIP3 share high but not complete homology

  • Verify whether your antibody's epitope is conserved between species

  • The BH3 domain-specific antibody recognizes both human and mouse BNIP3

• Expression Level Differences:

  • Baseline BNIP3 expression varies between tissues and between species

  • Normalize to appropriate housekeeping proteins for each species

  • Compare relative changes rather than absolute values when possible

• Experimental Conditions Adjustment:

  • Mouse tissues may require different fixation protocols than human samples

  • Optimization of antigen retrieval conditions may be necessary for each species

  • Consider titrating antibody concentrations separately for human and mouse samples

• Cross-Reactivity Verification:

  • Validate specificity in each species using knock-down/knock-out controls

  • Consider western blot confirmation of IHC/IF results to verify specific binding

  • Be cautious about cross-reactive bands/signals that may appear in one species but not the other

What are potential causes and solutions for inconsistent BNIP3 antibody performance across experiments?

How can researchers use anti-BNIP3 antibodies to study mitochondrial quality control mechanisms?

BNIP3 plays a critical role in mitochondrial quality control through its interaction with SPATA18/MIEAP, participating in the degradation of damaged proteins inside mitochondria . To investigate this function:

• Co-immunoprecipitation Approach:

  • Use anti-BNIP3 antibodies to pull down protein complexes

  • Detect interaction partners (SPATA18/MIEAP, BNIP3L/NIX) via western blotting

  • Analyze how these interactions change under mitochondrial stress conditions

• Confocal Microscopy Protocol:

  • Perform immunocytochemistry with anti-BNIP3 (1:100 dilution)

  • Co-stain with mitochondrial markers (MitoTracker or anti-TOMM20)

  • Analyze co-localization under normal and stressed conditions

  • Quantify mitochondrial morphology changes

• Functional Assays:

  • Induce mitochondrial damage (e.g., CCCP treatment, hypoxia)

  • Measure BNIP3 recruitment to damaged mitochondria

  • Assess mitochondrial membrane potential changes

  • Correlate BNIP3 expression with mitophagy markers

• Domain Function Analysis:

  • Use BH3 domain-specific antibodies to study domain-specific roles

  • Compare with antibodies targeting other regions of BNIP3

  • Analyze how post-translational modifications affect function

What methodological approaches can differentiate between parasitic NIP3 and mammalian BNIP3 in co-infection models?

For research involving both parasitic infections and mammalian BNIP3 function:

• Antibody Selection Strategy:

  • Choose antibodies with confirmed specificity to either BmNIP3 or mammalian BNIP3

  • Verify epitope sequences have minimal cross-reactivity

  • Test antibodies on purified recombinant proteins of both types

• Differential Detection Protocol:

  • Use size differences: BmNIP3 (~21 kDa native) vs. mammalian BNIP3 (~21.5 kDa calculated)

  • Employ species-specific secondary antibodies

  • Implement sequential immunofluorescence with distinct fluorophores

• Stage-Specific Analysis:

  • Target larval stages (L3, L4) for parasitic NIP3 detection, as BmNIP3 is highly expressed in these stages

  • Compare with adult stages where parasitic NIP3 expression is minimal

• Isotype Profile Assessment:

  • Analyze antibody isotype responses (IgG1, IgG2, IgG3, IgG4)

  • EN individuals show predominantly IgG1 and IgG2 responses to BmNIP3

  • Chronically infected patients show predominantly IgG3 responses

  • Microfilaremic individuals show elevated IgG1 responses

How can post-translational modifications of BNIP3 be effectively studied using available antibodies?

BNIP3 undergoes various post-translational modifications that affect its function. Researchers can study these using:

• Phosphorylation Analysis:

  • Immunoprecipitate BNIP3 using specific antibodies

  • Probe with anti-phosphoserine/threonine antibodies (1:1,000 dilution)

  • Compare phosphorylation status under different cellular conditions

  • Consider phosphatase treatments as controls

• Glycosylation Assessment:

  • BmNIP3 contains potential mucin-type O-glycosylation sites

  • Use specific glycosylation antibodies (anti-O-GlcNAc at 1:5,000 dilution)

  • Employ glycosidase treatments to confirm modification

  • Note that not all predicted modifications may be present (BmNIP3 was not detected as O-β-glycosylated despite predictions)

• Combined Approaches:

  • Use 2D gel electrophoresis to separate BNIP3 isoforms

  • Analyze molecular weight shifts (native BmNIP3 runs at ~21 kDa despite 15 kDa predicted size)

  • Employ mass spectrometry after immunoprecipitation for comprehensive PTM mapping

• Functional Correlations:

  • Compare antibodies targeting modified vs. unmodified forms

  • Analyze how modifications correlate with subcellular localization

  • Study how modifications affect protein-protein interactions

What considerations are important when using BNIP3 antibodies in immunological studies of parasitic infections?

When investigating immune responses to parasitic infections using BNIP3/NIP3 antibodies:

• Clinical Group Stratification:

  • Define subject groups carefully: Endemic Normal (EN), Microfilaremic (MF), Chronic Pathology (CP), and Non-Endemic Normal (NEN)

  • Different clinical groups show distinct isotype profiles against BmNIP3:

    • EN: Predominantly IgG1 and IgG2

    • CP: Predominantly IgG3

    • MF: High levels of IgG1

    • All groups show minimal IgG4 responses

• Cross-Reactivity Management:

  • Test for cross-reactivity between antibodies against parasitic NIP3 and human BNIP3

  • Consider pre-absorption steps to reduce non-specific binding

  • Include appropriate controls from non-endemic areas

• Stage-Specific Analysis:

  • BmNIP3 is differentially expressed across parasite life stages

  • Highest expression occurs in larval (L3 and L4) stages

  • Consider timing of sampling relative to infection status

• Methodological Adaptation:

  • ELISA: Use recombinant BmNIP3 as coating antigen (5 μg/mL)

  • Immunization protocols: Consider subcutaneous delivery with appropriate adjuvants

  • Serum dilutions: Optimize based on expected antibody titers in different clinical groups